Hematology-Oncology Associates of the Quad-Cities, PC
Breast Cancer Trials
Program for the Assessment of Clinical Cancer Tests (PACCT-1):
Trial Assigning IndividuaLized Options for Treatment:The TAILORx Trial—FOR Adjuvant node negative hormone receptor positive breast cancer using the Oncotype-DX testing.
CALGB 40101: Cyclophosphamide and Doxorubicin (CA 4 vs 6 Cycles) vs. Paclitaxel (12 vs. 18 weeks) as Adjuvant Therapy for Women with Node Negative Breast Cancer.
CALGB 40502: A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab- Paclitaxel or Ixabepilone Combined With Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer.
SWOG S0221 Phase III Trial of Continuous Schedule AC + G Vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer
E5103: A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
N0639: ALTTO: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Study A randomized, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer.
NSABP B-37: A Randomized Clinical Trial of Adjuvant Chemotherapy for Radically
Resected Loco-Regional Relapse of Breast Cancer
NSABP B-43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy.
NSABP PROTOCOL B-42: A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Cancer
IBCSG 24-02: A Phase III Trail Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer (SOFT).
IBCSG-25: A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer
E1105: A Randomized Phase III Double-Blind Placebo-Controlled Trial of First-line Chemotherapy and Trastuzumab with or without Bevacizumab for Patients with HER-2/NEU Over-expressing Metastatic Breast Cancer
CALGB 40302: Endocrine Therapy With or Without Inhibition of EGF and HER2 Growth Factor Receptors: a Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib (GW572016) for Postmenopausal Women with Hormone Receptor Positive Advanced Breast Cancer.
NCCTG 0733: Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 in HER2 + Breast Cancer Previously Treated with Trastuzumab and an Anthracycline and/or a Taxane
CALGB 40503: Endocrine Therapy in Combination with anti-VEGF Therapy: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab For Women with Hormone Receptor-Positive Advanced Breast Cancer
Genentech TDM4374: Phase II Study of Trastuzumab-MCC-DM1 for HER2+ breast cancer who have failed or cannot tolerate Lapatinib.
Trial Assigning IndividuaLized Options for Treatment:The TAILORx Trial—FOR Adjuvant node negative hormone receptor positive breast cancer using the Oncotype-DX testing.
CALGB 40101: Cyclophosphamide and Doxorubicin (CA 4 vs 6 Cycles) vs. Paclitaxel (12 vs. 18 weeks) as Adjuvant Therapy for Women with Node Negative Breast Cancer.
CALGB 40502: A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab- Paclitaxel or Ixabepilone Combined With Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer.
SWOG S0221 Phase III Trial of Continuous Schedule AC + G Vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer
E5103: A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
N0639: ALTTO: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Study A randomized, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer.
NSABP B-37: A Randomized Clinical Trial of Adjuvant Chemotherapy for Radically
Resected Loco-Regional Relapse of Breast Cancer
NSABP B-43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy.
NSABP PROTOCOL B-42: A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Cancer
IBCSG 24-02: A Phase III Trail Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer (SOFT).
IBCSG-25: A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer
E1105: A Randomized Phase III Double-Blind Placebo-Controlled Trial of First-line Chemotherapy and Trastuzumab with or without Bevacizumab for Patients with HER-2/NEU Over-expressing Metastatic Breast Cancer
CALGB 40302: Endocrine Therapy With or Without Inhibition of EGF and HER2 Growth Factor Receptors: a Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib (GW572016) for Postmenopausal Women with Hormone Receptor Positive Advanced Breast Cancer.
NCCTG 0733: Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 in HER2 + Breast Cancer Previously Treated with Trastuzumab and an Anthracycline and/or a Taxane
CALGB 40503: Endocrine Therapy in Combination with anti-VEGF Therapy: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab For Women with Hormone Receptor-Positive Advanced Breast Cancer
Genentech TDM4374: Phase II Study of Trastuzumab-MCC-DM1 for HER2+ breast cancer who have failed or cannot tolerate Lapatinib.
